Protein complexes are defined by the three‐dimensional structure of participating binding partners. Knowledge about these structures can facilitate the design of peptidomimetics which have been applied for example, as inhibitors of protein–protein interactions (PPIs). Even though β‐sheets participate widely in PPIs, they have only rarely served as the basis for peptidomimetic PPI inhibitors, in particular when addressing intracellular targets. Here, we present the structure‐based design of β‐sheet mimetics targeting the intracellular protein β‐catenin, a central component of the Wnt signaling pathway. Based on a protein binding partner of β‐catenin, a macrocyclic peptide was designed and its crystal structure in complex with β‐catenin obtained. Using this structure, we designed a library of bicyclic β‐sheet mimetics employing a late‐stage diversification strategy. Several mimetics were identified that compete with transcription factor binding to β‐catenin and inhibit Wnt signaling in cells. The presented design strategy can support the development of inhibitors for other β‐sheet‐mediated PPIs.
20 September 2019 in Angewandte Chemie International Edition
Protein complex formation depends on the interplay between preorganization and flexibility of the binding epitopes involved. The design of epitope mimetics typically focuses on stabilizing a particular bioactive conformation, often without considering conformational dynamics, which limits the potential of peptidomimetics against challenging targets such as transcription factors. We developed a peptide‐derived inhibitor of the NF‐Y transcription factor by first constraining the conformation of an epitope through hydrocarbon stapling and then fine‐tuning its flexibility. In the initial set of constrained peptides, a single non‐interacting α‐methyl group was observed to have a detrimental effect on complex stability. Biophysical characterization revealed how this methyl group affects the conformation of the peptide in its bound state. Adaption of the methylation pattern resulted in a peptide that inhibits transcription factor assembly and subsequent recruitment to the target DNA.
Protein complexes are defined by the three‐dimensional structure of participating binding partners. Knowledge about these structures can facilitate the design of peptidomimetics which have been applied for example, as inhibitors of protein–protein interactions (PPIs). Even though β‐sheets participate widely in PPIs, they have only rarely served as the basis for peptidomimetic PPI inhibitors, in particular when addressing intracellular targets. Here, we present the structure‐based design of β‐sheet mimetics targeting the intracellular protein β‐catenin, a central component of the Wnt signaling pathway. Based on a protein binding partner of β‐catenin, a macrocyclic peptide was designed and its crystal structure in complex with β‐catenin obtained. Using this structure, we designed a library of bicyclic β‐sheet mimetics employing a late‐stage diversification strategy. Several mimetics were identified that compete with transcription factor binding to β‐catenin and inhibit Wnt signaling in cells. The presented design strategy can support the development of inhibitors for other β‐sheet‐mediated PPIs.
19 April 2021 in Angewandte Chemie International Edition
Bicyclic peptidomimetics bind the transcriptional coactivator β‐catenin. A structure‐based design strategy has been applied to minimize a 52 amino acid binding motif into bicyclic 16‐mer β‐sheet mimetics. The biologically most active mimetic exhibits robust cellular uptake and inhibits Wnt signaling in a cell‐based assay, as reported by Tom N. Grossmann et al. in their Research Article (DOI: 10.1002/anie.202102082).
Bizyklische Peptidomimetika binden den transkriptionellen Coaktivator β‐Catenin. Eine strukturbasierte Designstrategie wurde angewandt, um ein 52 Aminosäuren umfassendes Bindungsmotiv in bicyclische 16‐mere β‐Sheet‐Mimetika zu minimieren. Das biologisch aktivste Mimetikum zeigt eine robuste zelluläre Aufnahme und hemmt die Wnt‐Signaltransduktion in einem zellbasierten Assay, wie Tom N. Grossmann et al. in ihrem Forschungsartikel berichten (DOI: 10.1002/ange.202102082).